Adaptimmune Announces Initiation of Myxoid/Round Cell Liposarcoma Study
December 05 2016 - 7:30AM
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell
therapy to treat cancer, today announced that it has initiated a
study of its NY‑ESO SPEAR™ T‑cells in myxoid/round cell liposarcoma
(MRCLS). Patient screening is underway, and the results from this
study in up to 15 patients will inform a potential future
registration trial. The initiation of screening in this study meets
a milestone set forth in the Company’s strategic collaboration
agreement with GlaxoSmithKline plc (LSE/NYSE: GSK).
This is an open-label pilot study in patients to assess
preliminary safety and efficacy in this new indication. Initially,
10 patients will be enrolled. If further characterization of the
treatment is required, up to 5 additional patients may be enrolled.
Eligible patients will be HLA-A*02:01, HLA‑A*02:05 and/or
HLA-A*02:06 with advanced (metastatic or inoperable) high grade
MRCLS whose tumor shows positive NY-ESO-1 expression defined as ≥30
percent of cells that are 2+ or 3+ by immunohistochemistry.
Patients will receive preconditioning with fludarabine and
cyclophosphamide at the same dose that is being used in
Cohort 4 of the Company’s ongoing synovial sarcoma study.
About MRCLSSoft tissue sarcomas can develop
from tissues like fat, muscle, nerves, fibrous tissues, blood
vessels, or deep skin tissues. There are approximately 50 types of
soft tissue sarcomas, including MRCLS. Myxoid/round cell
liposarcoma is associated with specific chromosomal translocations
and represents about 30 to 35 percent of liposarcomas and 5 to 10
percent of all adult soft tissue sarcomas. Myxoid/round cell
liposarcoma commonly presents at an age ranging from 35 to 55
years.
About AdaptimmuneAdaptimmune is a clinical
stage biopharmaceutical company focused on novel cancer
immunotherapy products based on its SPEAR (Specific Peptide
Enhanced Affinity Receptor) T-cell platform. Established in 2008,
the Company aims to utilize the body’s own machinery - the T-cell -
to target and destroy cancer cells by using engineered, increased
affinity TCRs as a means of strengthening natural patient T-cell
responses. Adaptimmune’s lead program is a SPEAR T-cell therapy
targeting the NY-ESO cancer antigen. Its NY-ESO SPEAR T-cell
therapy has demonstrated signs of efficacy and tolerability in
Phase 1/2 trials in solid tumors and in hematologic cancer types,
including synovial sarcoma and multiple myeloma. Adaptimmune has a
strategic collaboration and licensing agreement with
GlaxoSmithKline for the development and commercialization of the
NY-ESO TCR program. In addition, Adaptimmune has a number of
proprietary programs. These include SPEAR T-cell therapies
targeting the MAGE-A10 and AFP cancer antigens, which both have
open INDs, and a further SPEAR T-cell therapy targeting the MAGE-A4
cancer antigen that is in pre-clinical phase with IND acceptance
targeted for 2017. The Company has identified over 25 intracellular
target peptides preferentially expressed in cancer cells and is
currently progressing 12 through unpartnered research programs.
Adaptimmune has over 250 employees and is located in Oxfordshire,
U.K. and Philadelphia, USA. For more information:
http://www.adaptimmune.com
Forward-Looking StatementsThis release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995 (PSLRA). These
forward-looking statements involve certain risks and uncertainties.
Such risks and uncertainties could cause our actual results to
differ materially from those indicated by such forward-looking
statements, and include, without limitation: the success, cost and
timing of our product development activities and clinical trials
and our ability to successfully advance our TCR therapeutic
candidates through the regulatory and commercialization processes.
For a further description of the risks and uncertainties that could
cause our actual results to differ materially from those expressed
in these forward-looking statements, as well as risks relating to
our business in general, we refer you to our Quarterly Report on
Form 10-Q filed with the Securities and Exchange Commission (SEC)
on November 10, 2016, and our other SEC filings. The
forward-looking statements contained in this press release speak
only as of the date the statements were made and we do not
undertake any obligation to update such forward-looking statements
to reflect subsequent events or circumstances.
Adaptimmune Contacts
Investor Relations
Will Roberts
T: (215) 825-9306
E: will.roberts@adaptimmune.com
Juli P. Miller, Ph.D.
T: (215) 825-9310
E: juli.miller@adaptimmune.com
Media Relations
Margaret Henry
T: +44 (0)1235 430036
Mobile: +44 (0)7710 304249
E: margaret.henry@adaptimmune.com
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024